l 803087 tfa

L-803087 TFA is a highly potent and selective agonist of the somatostatin sst4 receptor, exhibiting a Ki value of 0.7 nM. It displays a remarkable selectivity, being over 280-fold more preferential for the sst4 receptor compared to other somatostatin receptors. Furthermore, L-803087 TFA promotes AMPA-mediated synaptic responses in hippocampal preparations and enhances kainate-induced seizures in mice.

L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and fatty acid metabolite, accumulates in the sarcolemma, disrupting the membrane lipid environment during ischemia. It inhibits K ATP channel activity by interacting with Kir6.2 without altering single-channel conductance [1].

L-803087 is a potent and selective agonist of the growth inhibitor sst4 receptor with a Ki value of 0.7 nM for sst4, which is more than 280-fold more selective than other growth inhibitory receptors.L-803087 induced AMPA-mediated synaptic responses in the hippocampus in vitro, and in vivo increased seizures in alginate-induced seizure-busting mice.

L-K6L9, a cytolytic peptide comprised of L-isomer leucine and lysine, demonstrates cytotoxicity against both androgen-independent (LNCaP-CL1) and androgen-dependent (22Rv1 and LNCaP) human prostate cancer cells, with LC50 values of 4, 4, and 6 µM, respectively. It also affects non-cancerous cells, including NIH3T3 mouse fibroblasts and OL human foreskin fibroblasts, with LC50s of 7 and 5 µM, respectively. Furthermore, at a concentration of 100 µM, L-K6L9 induces hemolysis in isolated human erythrocytes.

L-GO-203 TFA is a potent inhibitor of the MUC1-C oncoprotein, serving as an anticancer peptide that targets intracellular proteins [1].

MNI-caged-L-glutamate, a derivative of glutamate conjugated with a 4-methoxy-7-nitroindolinyl (MNI) photoprotective group, remains pharmacologically inactive at neuronal glutamate receptors at concentrations up to mM. Upon light exposure (300 - 380 nm excitation), it rapidly releases L-glutamate by cleaving the MNI group within submicroseconds. This characteristic enables the investigation of fast synaptic glutamate receptor mechanisms in situ.

L-R4W2 TFA acts as a potent antagonist of vanilloid receptor 1 (VR1, TRPV1), demonstrating significant inhibitory activity with an IC50 value of 0.1 μM. This compound potentially offers powerful analgesic properties [1] [2].